GALENICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.85 CHF | +0.58% |
|
-3.92% | -3.99% |
| Apr. 17 | Switzerland's Galenica Issues CHF100 Million Bond Due 2031 | MT |
| Mar. 14 | GALENICA : FY23 one-offs shroud decent underlying profitability growth |  |
| Sales 2024 * | 3.92B 4.31B | Sales 2025 * | 4.08B 4.48B | Capitalization | 3.46B 3.8B |
|---|---|---|---|---|---|
| Net income 2024 * | 174M 191M | Net income 2025 * | 183M 201M | EV / Sales 2024 * | 1.02 x |
| Net Debt 2024 * | 540M 593M | Net Debt 2025 * | 510M 560M | EV / Sales 2025 * | 0.97 x |
| P/E ratio 2024 * |
20.1
x | P/E ratio 2025 * |
18.9
x | Employees | 6,181 |
| Yield 2024 * |
3.29% | Yield 2025 * |
3.41% | Free-Float | 99.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Galenica AG
More recommendations
More press releases
More news
| 1 day | -0.11% | ||
| 1 week | -4.26% | ||
| Current month | -7.45% | ||
| 1 month | -7.32% | ||
| 3 months | -6.45% | ||
| 6 months | +6.02% | ||
| Current year | -4.33% |
1 week
69.30
71.35
1 month
69.3075.55
Current year
69.3078.15
1 year
65.1082.20
3 years
60.5582.20
5 years
47.5882.20
10 years
41.8082.20
| Managers | Title | Age | Since |
|---|---|---|---|
Marc Werner
CEO | Chief Executive Officer | 57 | - |
| Director of Finance/CFO | 58 | 16-12-31 | |
Lukas Ackermann
CTO | Chief Tech/Sci/R&D Officer | 52 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Etienne Jornod
CEO | Chief Executive Officer | 71 | 95-12-31 |
Jörg Zulauf
BRD | Director/Board Member | 66 | 23-05-02 |
| Director/Board Member | 62 | 16-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.18% | 5 M€ | -.--% | - | |
| 0.17% | 1,120 M€ | -1.82% | ||
| 0.07% | 773 M€ | -.--% | - | |
| 0.02% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 69.85 | +0.58% | 57 943 |
| 24-04-17 | 69.45 | -0.86% | 63,883 |
| 24-04-16 | 70.05 | -0.78% | 97,371 |
| 24-04-15 | 70.6 | -0.07% | 72,600 |
| 24-04-12 | 70.65 | -2.82% | 133,519 |
Delayed Quote Swiss Exchange, April 18, 2024 at 03:21 am EDT
More quotes
Galenica AG, previously Galenica Sante Ltd, is a Switzerland-based healthcare services and products provider. The Company's business i divided into three business sectors: Retail, Products & Brands, and Services. The Company manages a locally established pharmacies network in Switzerland. It develops and distributes its own product portfolio, as well as cooperates with a range of business partners, such as Pierre Fabre, Ales Groupe and Vitor Consumer Health for marketing and distribution of such brands as Perskindol, Triofan, A-Derma, Lierac, Phyto, Anti-Brumm and Algifor. Galenica Sante's Services business sector is responsible for management of such logistics sector companies as Galexis, Unione Farmaceutica Distribuzione, Alloga and Medifilm.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
69.45
CHF
Average target price
76.25
CHF
Spread / Average Target
+9.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.33% | 3.79B | |
| +13.59% | 69.11B | |
| +5.67% | 25.91B | |
| +5.02% | 8.01B | |
| -2.98% | 7.91B | |
| -27.52% | 7.27B | |
| -0.12% | 4.51B | |
| +21.54% | 4.48B | |
| -2.45% | 3.95B | |
| +23.90% | 3.7B |
- Stock Market
- Equities
- GALE Stock
